pharmacokinetics is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Free peptide form |
| Molecular mass | About 751.9 Da | Calculated average mass |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form TKPRPGP |
| Structural basis | Tuftsin analogue | Extended version of a natural tetrapeptide |
| Development origin | Russian Academy of Sciences | Work carried out from the 1980s onward |
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The letter was seized on by the Committee, who immediately released £4,000 to begin development. They petitioned Hugh Dowding, the Air Member for Supply and Research, to ask the Treasury for another £10,000. Dowding was extremely impressed with the concept, but demanded a practical demonstration before further funding was released. Wilkins suggested using the new 10 kW, 49.8 m BBC Borough Hill shortwave station in Daventry, Northamptonshire as a suitable ad hoc transmitter. The receiver and an oscilloscope were placed in a delivery van the RRS used for measuring radio reception around the countryside. On 26 February 1935, they parked the van in a field near Upper Stowe and connected it to wire antennas stretched across the field on top of wooden poles. A Handley Page Heyford made four passes over the area, producing clearly notable effects on the CRT display on three of the passes. A memorial stone was placed at the site of the test. Observing the test were Watt, Wilkins, and several other members of the RRS team, along with Rowe representing the Tizard Committee. Watt was so impressed he later claimed to have exclaimed: "Britain has become an island again!" Rowe and Dowding were equally impressed. It was at this point that Watt's previous agitation over development became important; NPL management remained uninterested in practical development of the concept, and was happy to allow the Air Ministry to take over the team.
On 9 November 1918, Philipp Scheidemann, a Social Democrat, proclaimed the German Republic, marking Germany's transition to a federal democratic state. Germany's new leadership signed the Treaty of Versailles in 1919, accepting defeat by the Allies. Germans perceived the treaty as humiliating, which was seen by historians as influential in the rise of Adolf Hitler. Germany lost around 13% of its European territory and ceded all of its colonial possessions. On 11 August 1919, President Friedrich Ebert signed the democratic Weimar Constitution. Communists briefly seized power in Bavaria and a few larger cities, while conservative elements failed to overthrow the central government in the 1920 Kapp Putsch. The occupation of the Ruhr by Belgian and French troops and a period of hyperinflation followed. A plan to restructure Germany's war reparations and the creation of a new currency in 1924 helped stabilise the government and ushered in the Golden Twenties, an era of artistic innovation and liberal cultural life. In 1929, the Great Depression hit Germany, and by 1932 the unemployment rate had risen to nearly 30%. The Nazi Party led by Adolf Hitler became the largest party in the Reichstag after the election of July 1932, and President Hindenburg appointed Hitler as chancellor on 30 January 1933. After the Reichstag fire, a decree abrogated basic civil rights, and the first Nazi concentration camp opened. On 23 March 1933, the Enabling Act gave Hitler unrestricted legislative power, overriding the constitution, and marked the beginning of Nazi Germany.
== Legal and regulatory status == European Union: In the EU, Good Clinical Practice is backed and regulated by formal legislation contained in the Clinical Trial Regulation (Officially Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC). A similar guideline for clinical trials of medical devices is the international standard ISO 14155, which is valid in the European Union as a harmonized standard. These standards for clinical trials are sometimes referred to as ICH-GCP or ISO-GCP to differentiate between the two and the lowest grade of recommendation in clinical guidelines. United States: Although ICH GCP guidelines are recommended by the Food and Drug Administration (FDA), they are not statutory in the United States. The National Institutes of Health requires NIH-funded clinical investigators and clinical trial staff who are involved in the design, conduct, oversight, or management of clinical trials to be trained in Good Clinical Practice.
Sources: en.wikipedia.org
=== Hormone replacement therapy === The doses of hormone replacement therapy (HRT) for CAIS individuals are debatable. Some have hypothesized that supraphysiological levels of estrogen may reduce the diminished bone mineral density associated with CAIS, while counter-arguments suggested a lower dose of HRT because levels of estrogen in CAIS individuals are normally below the female range before gonadectomy. Data has been published that suggests affected women who were not compliant with estrogen replacement therapy, or who had a lapse in estrogen replacement, experienced a more significant loss of bone mineral density. Progestin replacement therapy is usually seldom initiated as well. Androgen replacement has been reported to increase a sense of well-being in gonadectomized people with CAIS, although the mechanism by which this benefit is achieved is not well understood.
The stationary phase is adhered to the inside of a small-diameter (commonly 0.53 – 0.18mm inside diameter) glass or fused-silica tube (a capillary column) or a solid matrix inside a larger metal tube (a packed column). It is widely used in analytical chemistry; though the high temperatures used in GC make it unsuitable for high molecular weight biopolymers or proteins (heat denatures them), frequently encountered in biochemistry, it is well suited for use in the petrochemical, environmental monitoring and remediation, and industrial chemical fields. It is also used extensively in chemistry research.
Blasticidin S is an antibiotic that is used in biology research for selecting cells in cell culture. Cells of interest can express the blasticidin resistance genes BSD or bsr, and can then survive treatment with the antibiotic. Blasticidin S is a nucleoside analogue antibiotic, resembling the nucleoside cytidine. Blasticidin works against human cells, fungi, and bacteria, all by disrupting protein translation. It was originally described by Japanese researchers in the 1950s seeking antibiotics for rice blast fungus.
For example, SEC-MALS analysis of a monodisperse protein will show that the entire peak consists of molecules with the same molar mass, something that is not possible with standard SEC analysis. Determination of molar mass with SLS requires combining the light scattering measurements with concentration measurements. Therefore SEC-MALS typically includes the light scattering detector and either a differential refractometer or UV/Vis absorbance detector. In addition, MALS determines the rms radius Rg of molecules above a certain size limit, typically 10 nm. SEC-MALS can therefore analyze the conformation of polymers via the relationship of molar mass to Rg. For smaller molecules, either DLS or, more commonly, a differential viscometer is added to determine hydrodynamic radius and evaluate molecular conformation in the same manner. In SEC-DLS, the sizes of the macromolecules are measured as they elute into the flow cell of the DLS instrument from the size exclusion column set. The hydrodynamic size of the molecules or particles are measured and not their molecular weights. For proteins a Mark-Houwink type of calculation can be used to estimate the molecular weight from the hydrodynamic size. A major advantage of DLS coupled with SEC is the ability to obtain enhanced DLS resolution. Batch DLS is quick and simple and provides a direct measure of the average size, but the baseline resolution of DLS is a ratio of 3:1 in diameter. Using SEC, the proteins and protein oligomers are separated, allowing oligomeric resolution. Aggregation studies can also be done using ASEC.
Sources: en.wikipedia.org
Blood flows from the heart through arteries, which branch and narrow into arterioles, and then branch further into capillaries where nutrients and wastes are exchanged. The capillaries then join and widen to become venules, which in turn widen and converge to become veins, which then return blood back to the heart through the venae cavae. In the mesentery, metarterioles form an additional stage between arterioles and capillaries. Individual capillaries are part of the capillary bed, an interweaving network of capillaries supplying tissues and organs. The more metabolically active a tissue is, the more capillaries are required to supply nutrients and carry away products of metabolism. There are two types of capillaries: true capillaries, which branch from arterioles and provide exchange between tissue and the capillary blood, and sinusoids, a type of open-pore capillary found in the liver, bone marrow, anterior pituitary gland, and brain circumventricular organs. Capillaries and sinusoids are short vessels that directly connect the arterioles and venules at opposite ends of the beds. Metarterioles are found primarily in the mesenteric microcirculation. Lymphatic capillaries are slightly larger in diameter than blood capillaries, and have closed ends (unlike the blood capillaries open at one end to the arterioles and open at the other end to the venules). This structure permits interstitial fluid to flow into them but not out. Lymph capillaries have a greater internal oncotic pressure than blood capillaries, due to the greater concentration of plasma proteins in the lymph.
== Double dilution method == The single dilution method requires the knowledge of the isotopic composition of the isotopically enriched analyte (RB) and the amount of the enriched analyte added (nB). Both of these variables are hard to establish since isotopically enriched substances are generally available in small quantities of questionable purity. As a result, before isotope dilution is performed on the sample, the amount of the enriched analyte is ascertained beforehand using isotope dilution. This preparatory step is called the reverse isotope dilution and it involves a standard of natural isotopic-composition analyte (denoted as A*). First proposed in the 1940s and further developed in the 1950s, reverse isotope dilution remains an effective means of characterizing a labeled material.
== Illegal drugs == An illegal drug trade operates to distribute illegal drugs. The trade of illegal drugs overlaps with trade in contraband of all sorts. Illegal drug distribution does not overlap in obvious ways with the legal trade of legal drugs.
King was also faculty senior scientist at the Lawrence Berkeley National Laboratory and was program leader for chemical processes in the Energy and Environment Division from 1978 to 1981. He was one of the founders of the Council for Chemical Research in 1981. In 1990, King co-founded the Separations Division of AIChE and served as its first chair.
This inherent mutability of the tulip even led the Ottoman Turks to believe that nature cherished this flower above all others. The Dutch regarded the flower's lack of scent as a virtue, representing chasteness. The Black Tulip (1850) is a historical romance by Alexandre Dumas, père. The story takes place in the Dutch city of Haarlem, where a reward is offered to the first grower who can produce a truly black tulip. The tulip occurs on a number of the Major Arcana cards of occultist Oswald Wirth's deck of Tarot cards, specifically the Magician, Emperor, Temperance and the Fool, described in his 1927 work Le Tarot, des Imagiers du Moyen Âge.
Sources: en.wikipedia.org
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.
The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.
No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.